SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
- Evaluated articles (Rapid Reviews Infectious Diseases)
Abstract
We analyzed 21 676 residual specimens from Ontario, Canada collected March–August 2020 to investigate the effect of antibody decline on SARS-CoV-2 seroprevalence estimates. Testing specimens orthogonally using Abbott (anti-nucleocapsid) and Ortho (anti-spike) assays, seroprevalence estimates were 0.4%–1.4%, despite ongoing disease activity. The geometric mean concentration (GMC) of antibody-positive specimens decreased over time (P = .015), and GMC of antibody-negative specimens increased over time (P = .0018). Association between the 2 tests decreased each month (P < .001), suggesting anti-nucleocapsid antibody decline. Lowering Abbott antibody index cutoff from 1.4 to 0.7 resulted in a 16% increase in positive specimens.
Article activity feed
-
Strength of evidence
Reviewers: Samreen Zaidi | 📗📗📗📗◻️
Roger Dodd (American Red Cross) | 📒📒📒◻️◻️ -
-
Roger Dodd
Review 2: "SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline"
This study cautiously asserts that the outcome of a seroprevalence study is impacted by the declining prevalence rate, which impacts the sensitivity. Reviewers suggest the conclusion is rational and largely justifiable but limited by the data they utilize.
-
Samreen Zaidi
Review 1: "SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline"
This study cautiously asserts that the outcome of a seroprevalence study is impacted by the declining prevalence rate, which impacts the sensitivity. Reviewers suggest the conclusion is rational and largely justifiable but limited by the data they utilize.
-
SciScore for 10.1101/2020.09.28.20200915: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Ethics: Ethics approval for the serosurveys was granted by the PHO Ethics Review Board Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Laboratory testing: Using an orthogonal testing approach, we first tested specimens with the Abbott Architect SARS-CoV-2 IgG test (Abbott Laboratories, USA), which detects anti-nucleocapsid (N) antibodies, then tested positive samples with the Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG test (Ortho-Clinical Diagnostics, Inc., USA), which detects anti-spike (S) antibodies [8]. anti-nucleocapsid (N)suggeste…SciScore for 10.1101/2020.09.28.20200915: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Ethics: Ethics approval for the serosurveys was granted by the PHO Ethics Review Board Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Laboratory testing: Using an orthogonal testing approach, we first tested specimens with the Abbott Architect SARS-CoV-2 IgG test (Abbott Laboratories, USA), which detects anti-nucleocapsid (N) antibodies, then tested positive samples with the Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG test (Ortho-Clinical Diagnostics, Inc., USA), which detects anti-spike (S) antibodies [8]. anti-nucleocapsid (N)suggested: NoneAnti-SARS-CoV-2 IgGsuggested: Noneanti-spike (S)suggested: NoneSpecimens that were positive using both tests were considered positive for SARS-CoV-2 antibodies. SARS-CoV-2suggested: NoneSoftware and Algorithms Sentences Resources Laboratory testing: Using an orthogonal testing approach, we first tested specimens with the Abbott Architect SARS-CoV-2 IgG test (Abbott Laboratories, USA), which detects anti-nucleocapsid (N) antibodies, then tested positive samples with the Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG test (Ortho-Clinical Diagnostics, Inc., USA), which detects anti-spike (S) antibodies [8]. Abbott Architectsuggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)Abbott Laboratoriessuggested: NoneTo explore the effect of lowering the Abbott index value on population seroprevalence, we analyzed a subset of specimens with an index value of 0.7, otherwise maintaining the same orthogonal approach as above. Abbottsuggested: (Abbott, RRID:SCR_010477)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-